AD
----

Award Number: DAMD17-94-J-4294

TITLE: University of Kansas Cancer Center Breast Tissue and Serum Repository Core Facility

PRINCIPAL INVESTIGATOR: Jonathan J. Li, Ph.D.

CONTRACTING ORGANIZATION: University of Kansas Medical Center Kansas City, Kansas 66160-7700

REPORT DATE: October 1999

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

### REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503 3. REPORT TYPE AND DATES COVERED 2. REPORT DATE 1. AGENCY USE ONLY (Leave Final (23 Sep 94 - 22 Sep 99) October 1999 blank) 5. FUNDING NUMBERS 4. TITLE AND SUBTITLE University of Kansas Cancer Center Breast Tissue and Serum DAMD17-94-J-4294 Repository Core Facility 6. AUTHOR(S) Jonathan J. Li, Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER University of Kansas Medical Center Kansas City, Kansas 66160-7700 E-MAIL: ili 1 @kumc.edu 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING **AGENCY REPORT NUMBER** U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION CODE 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; Distribution Unlimited 13. ABSTRACT (Maximum 200 Words) With the support of the U.S. Army Medical Research and Development, the University of Kansas Medical Center and the Kansas Cancer Institute has established a Breast Tissue and Serum Repository (BTSR) Core Facility, the first such facility in the lower Midwest. Funding of this core facility has served as the basis for its recent expansion to other female endocrine gynecologic cancers and the endocrine-associated male prostate cancer. The BTSR is fully supported by the Department of Surgery and Pathology, and will serve research needs not only at KU Medical Center, but to other institutions in the Kansas City Metropolitan area, and throughout the states of Kansas and Missouri. It is anticipated that in future years, the BTSR, with its systematic collection of normal and malignant tissues, including corresponding serum and lymphocyte samples, will serve as an increasingly important function for investigator-initiated cancer research studies.

14. SUBJECT TERMS

Breast, Endometrial, Ovarian, Prostate Cancer

17. SECURITY CLASSIFICATION OF THIS PAGE Unclassified

18. SECURITY CLASSIFICATION OF ABSTRACT Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified

Unclassified

15. NUMBER OF PAGES

58

16. PRICE CODE

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

#### **FOREWORD**

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 $\underline{x}$  In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature

Date

### TABLE OF CONTENTS

Introductio	n
Body	3
I. Backg	ground3
II. Expe	rimental Methods3
Patien	its
	e Samples3
	Samples6
	hocyte Samples7
	ge and Cataloging7
Results	8
Conclusion	s
Appendix	
Item 1.	Request for Participation, Informed Consent, and Questionnaire for Breast Surgery
Item 2.	Request for Participation, Informed Consent, and Questionnaire for Gynecological Surgery
Item 3.	Request for Participation, Informed Consent, and Questionnaire for Prostate Surgery
Item 4.	Protocol for Breast Tissue Procurement
Item 5.	Protocol for Prostate Tissue Procurement
Item 6.	Protocols for Serum and Lymphocyte Separation
Item 7.	Members of the Committee on Human Tissue Specimen Usage

#### INTRODUCTION

Breast cancer (BC) is the most prevalent of all cancer diseases in women throughout the world. In the USA, the risk of women developing BC by age 85 years is currently about one in eight. The cause(s) of BC and the means to predict who will develop it are currently not well-understood. Recognizing the cause(s) and possible susceptibility to BC are essential steps to the successful prevention of this prevalent disease in the future. Similarly, there is a paucity of knowledge related to early detection of BC, because screening procedures, while highly improved, do not allow detection of BC at the earliest and most curable stages. The development of the Breast Tissue and Serum Repository (BTSR) Core Facility at the Division of Etiology and Prevention of Hormonal Cancers (DEPHC), Kansas Cancer Institute (KCI) of the University of Kansas Medical Center (KUMC) has been an important step to address these issues at this institution.

A main focus of the Division of Etiology and Prevention of Hormonal Cancers (DEPHC) is to assist, complement, and expand ongoing programs, as well as to develop new ones related to the molecular biology and cytogenetics of hormone-related cancer research at KCI/KUMC. Although it is evident that the etiology of human BC is multifactorial, a central emphasis of the DEPHC is that hormones, particularly estrogens and progestins, play a critical role in BC causation, progression, and dependency, since it is increasingly apparent that both endogenous and exogenous estrogens and progesterional agents are critically involved in the etiology and development of human BC.

The BTSR's purpose is to facilitate investigator-initiated research to perform correlation studies on the incidence of possible premalignant and malignant breast lesions with genetic and variable biomarkers (e.g., receptors, hormones, cellular proteins, protooncogenes, tumor suppressor genes), and to assess the presence of potential carcinogens.

#### **BODY**

### I. Background

With the funding provided, the BTSR has been operational for 53 months. Dr. Jonathan J. Li continues as Director, Dr. Sara Antonia Li is the Associate Director, Ms. Jodi Ballenger is the Biologist II, and Ms. Stephanie Parks was the secretary until June 25, 1999.

### II. Experimental Methods

#### **Patients**

The BTSR biologist receives the daily surgical schedule for breast, endometrium, ovarian, and prostate surgeries. Three days before a patient is scheduled to have surgery, she/he is required to go to the Outpatient Laboratory to have her/his blood drawn for various presurgical tests. The BTSR biologist is stationed in the Outpatient Laboratory at the time of each of these appointments to be sure that extra blood is drawn and to label the blood vials with the proper outpatient laboratory labels, which include the patient's name and hospital patient identification number.

In addition, the BTSR biologist gives the patient consent forms for donating blood to the BTSR, asking the patient to sign them, and to complete the Personal Health History questionnaire. After the patient completes the appropriate questionnaire, the BTSR biologist writes the six-digit specimen-specific identification number on the upper right-hand corner of the front page of the questionnaire. Copies of the Request for Participation in the BTSR, Informed Consent, and Patient Questionnaires for Breast, Gynecological, and Prostate Surgery are included in the Appendix under Items 1 to 3. The patient questionnaire for gynecological surgeries (endometrium and ovarian cancer specimens) is identical to that used for breast cancer patients.

### Tissue Samples

Breast, endometrium, and ovarian tissue samples for the KCI-BTSR are acquired from female patients undergoing either breast reductions, biopsies, lumpectomies, mastectomies, or hysterectomies and/or oophorectomies for malignant and nonmalignant conditions. Prostate tissue is collected from male patients undergoing prostectomies. Copies of the protocols for breast and prostate tissue procurement are included in the Appendix under Items 4 and 5.

All the specimens are handled in a timely fashion in order to preserve the integrity of the tissues appropriately. Normal, abnormal, and neoplastic tissues are placed on a frozen cutting board and delivered, within 10 min of excision, to the Surgical Pathology Laboratory. At the lab, a certified

pathologist immediately evaluates the tumors, and frozen sections are prepared for diagnosis. When sufficient amount of tissue is available, the pathologist cuts tumor/normal tissue specimens for the BTSR biologist.

When the amount of tissue is adequate, one portion is allocated for frozen sections, and the remaining tissue is labeled with a proper bar-code label (specimen-specific identification number) and snap-frozen in a polypropylene container. Tissue samples destined for frozen sections are covered with tissue-embedding medium in a cryomold, placed in an airtight polypropylene container, similarly bar-code labeled, and snap-frozen immediately in an  $N_2$  container before storage in the BTSR freezer.

Each specimen is assigned a unique six-digit specimen-specific identification number, which is assigned sequentially. The same bar-code number is used to identify each individual patient malignant and healthy adjacent tissues, and blood productss. All tissue aliquots derived from the same tissue are assigned the same six-digit number. This six-digit specimen-specific identification number is shown on the bar-code with which the biologist labels each container and slide.

Surgical Pathology requisition forms are computer generated by the Surgery Department and accompany the specimens when delivered to the Pathology Laboratory. The information in the forms includes: Hospital patient identification number, surgeon's name, patient's name and age, date of surgery, and site of specimen. In addition, Surgical Pathology personnel write the Surgical Pathology identification number on the requisition form, and the surgical pathologist measures the tumor before it is divided, indicating the size of the tumor in the report. The biologist records the BTSR specimen-specific identification number on the requisition form, makes a copy of this form, and takes the it to the BTSR along with the specimens. These data are entered into the BTSR database.

Examples of sample storage data for breast and prostate tissues.

The following tests are routinely carried out on all malignant breast biopsy samples at KUMC.

- (1) A complete surgical pathology analysis, including size, tumor characteristics, histological type and grade, etc.
- (2) Estrogen and progesterone receptor analysis.
- (3) Immunostaining for p53 and HER-2/neu.
- (4) Ploidy analysis by flow cytometry or image analysis.

BTSR personnel can retrieve the results of all these tests as soon as they are available and enter the information into the BTSR database, as described below in Cataloging and Storage. Estrogen and progesterone tumor status are obtained from the Clinical Laboratory and the ploidy analysis from the Flow Cytometry Laboratory, while the rest of the test results are obtained from the Surgical Pathology Department.

### Serum Samples

Blood samples from both women and man undergoing tumor removal, and women at the KCI High Risk Breast Clinic are submitted to the BTSR.

Women who are considered at high risk for breast cancer are eligible to participate in the KCI High-Risk Breast Clinic. In general, eligible women include those between 30 and 55 years of age who have at least one of the following conditions: a first-degree relative who has had breast cancer, or, in herself, precancerous mastopathy or prior node-negative breast cancer in one breast.

The High-Risk Breast Clinic is located at the KU Cancer Center Comprehensive Outpatient Diagnostic and Treatment Center. During each patient's first visit to the clinic, blood is drawn for various medical tests. The BTSR biologist is responsible for securing the schedule of these visits in advance and advising the clinic to draw one extra vial of blood from each new patient for the BTSR. An identical procedure, described above, for securing the blood and completed questionnaire from breast surgery patients at the Outpatient Laboratory is followed for new patients seen at the High-Risk Breast Clinic.

When blood specimens are received at the BTSR, the biologist processes the blood before the specimens are cataloged and stored in the freezer. Copies of the protocols for serum and lymphocyte separation are in the Appendix as Item 6. Each container is labeled with the proper barcode label and snap-frozen. The labels are scanned and the appropriate data entered.

The specimen-specific number on the bar-code label is assigned to all specimens obtained. When applicable, the six-digit identification number is identical to the number assigned to the tissue specimen for the same patient.

### **Lymphocyte Samples**

The BTSR has the capacity to separate and freeze lymphocytes from peripheral blood when a special request is received. Blood is collected in heparin-containing tubes.

After all serum and lymphocytes samples are separated and labeled, they are stored in a -80°C freezer and the data regarding storage location in the Location Table of the database are recorded. The data include specimen identification number and sample location, including freezer shelf, box, and cubicle number. This allows the BTSR staff to locate all specimens quickly and efficiently.

### **Storage and Cataloging**

When a tissue sample is received at the BTSR, the specimen bar codes are scanned into the Biopsy Table or the Healthy Adjacent Table, as appropriate. The unique hospital patient identification number, the date when the specimen was received at the BTSR, the hospital of origin, the total amount of tissue, the surgical date, and all other data shown on the surgical requisition form that accompanies each specimen are recorded and stored in a computer.

All specimen-specific and patient-specific data are maintained in the computerized Repository Database Management system. In the Repository Database, the key fields are the unique specimen number, the hospital patient identification number, and the Surgical Pathology identification number. This combination serves as a unique patient identifier. Any or all of the tables within the database are linked using these three fields.

When a patient questionnaire is delivered to the BTSR, it is labeled with the appropriate bar code. The six-digit identification number matches those of the specimens from the same patient. The questionnaire labels are then scanned and the data entered into the Demographic/Life Style Table. The data requested include demographic, physical, and lifestyle information. Specifically, questions concern age, racial/ethnic background, marital status, religion, weight, height, education, occupation, family income, family history of cancer, reproductive status, and alcohol/tobacco history. To maintain confidentiality, all questionnaires are filed and locked up in a secure location after the data are entered into the database.

### **RESULTS**

The total number of breast, endometrial, ovarian, and prostate tissue specimens with accompanying blood products (serum, lymphocytes, or plasma) and histology blocks is summarized on Table 1.

Table 1. Specimen Update 10/22/99

	BREAST TISSUE			
	Non-Malignant	Normal		
Total Samples	86	129	24	
Blood Products*	55	50	1	
Histology Blocks	56	81	17	
Complete Sets	32	33	1	

<sup>\*</sup> Blood products: Serum, lymphocytes, or plasma samples

	ENDOMETRIAL TISSUE			
	Malignant			
Total Samples	21	60		
Blood Products*	15	54		
Histology Blocks	17	31		
Complete Sets	12	29		

<sup>\*</sup> Blood products: Serum, lymphocytes, or plasma samples

	OVARIAN TISSUE		
	Malignant	Non-Malignant	
Total Samples	17	75	
Blood Products*	16	67	
Histology Blocks	11	50	
Complete Sets	11	49	

<sup>\*</sup> Blood products: Serum, lymphocytes, or plasma samples

	PROSTATE TISSUE			
	Malignant	Non-Malignant	Normal	
Total Samples	7	6	1	
Blood Products*	7	6	1	
Complete Sets	7	6	1	

<sup>\*</sup> Blood products: Serum, lymphocytes, or plasma samples

The BTSR has collected plasma in addition to serum and lymphocytes. The collection of these specimens is summarized on Table 2. For surgical patients from whom tissue is not available, blood is still collected for the BTSR. However, it is not always available due to patient refusal.

Table 2. Blood Products Update 10/22/99

	BREAST			
	Total Samples	Malignant	Non-Malignant	
Serum Samples	173	105	70	
Lymphocyte Samples	157	93	63	
Plasma Samples	62	37	27	

	ENDOMETRIUM				
	Total Samples	Malignant	Non-Malignant		
Serum Samples	69	16	56		
Lymphocyte Samples	67	16	54		
Plasma Samples	21	8	14		

	OVARY			
	Total Samples	Malignant	Non-Malignant	
Serum Samples	82	18	67	
Lymphocyte Samples	79	18	64	
Plasma Samples	30	8	22	

	PROSTATE				
	Total Samples	Malignant	Non-Malignant		
Serum Samples	9	7	6		
Lymphocyte Samples	9	7	6		
Plasma Samples	3	3	0		

To use the specimens collected by the BTSR, KUMC and outside investigators submit proposal to the BTSR. When received, the proposals are reviewed by the BTSR Committee on Human Tissue Specimen Usage for approval. The list of the members of the committee has been included in the Appendix as Item 7. The following investigators are currently approved for specimen use.

% Estimated Use						
Investigator	1996	1997	1998	1999	Research Support	
Jonathan J. Li, Ph.D. (KUMC) Sara Antonia Li, Ph.D.	5%	5%	5%	5%	NCI 5 R01 CA 58030-04 NCI 5 R01 CA 58030-05 NCI 1 R01 CA 64047-03	
(KUMC)  Walter T. Imagawa, Ph.D. (KUMC)	10%	10%	10%		ACS RD-55 NCI CA 68414-01 USAMRMC BC960604	
Gregory Reed, Ph.D. (KUMC)	10%	10%	10%	10%	Dept. of Pharmacology institutional funds	
Carol Fabian, M.D. (KUMC)	15%	15%	15%		NCI P01 CA 72094 NCI U01 CA 72296 NCI MAA NCI CN 45593-32 NCI N01 CN 65024-32	
<i>Dr. Lin Tao</i> (Uni. Missouri – Kansas City)		10%	10%		NIH KS-34647	
Leslie Heckert, Ph.D. (KUMC)		10%	10%		Kansas Cancer Institute institutional funds	
Tsuneo Suzuki, M.D., Ph.D. (KUMC)		10%	10%		NIH P01 CA 54474	
<i>Eric Elsinghorst</i> , Ph.D. (Uni. Kansas – Lawrence		5%	5%		Dept. of Microbiology institutional funds	
Wade Bushman, M.D., Ph.D. (N.W. Univ. Medical School Chicago)				3%	NIH funding	

#### CONCLUSIONS

With the support of the U.S. Army Medical Research and Development, the University of Kansas Medical Center and the Kansas Cancer Institute has established a Breast Tissue and Serum Repository (BTSR) Core Facility, the first such facility in the lower Midwest. Funding of this core facility has served as the basis for its recent expansion to other female endocrine gynecologic cancers and the endocrine-associated male prostate cancer. The BTSR is fully supported by the Departments of Surgery and Pathology, and will serve research needs not only at KU Medical Center, but to other institutions in the Kansas City Metropolitan area, and throughout the states of Kansas and Missouri. It is anticipated that in future years, the BTSR, with its systematic collection of normal and malignant tissues, including corresponding serum and lymphocyte samples, will serve as an increasingly important function for investigator-initiated cancer research studies.

## The University of Kansas Medical



### To: All Patients Scheduled for Breast Surgery

A Request for Participation in the Tissue and Serum Repository

The University of Kansas Medical Center has established a Tissue and Serum Repository. One main purpose of this Repository is to document, cryopreserve, and store serum and samples of breast tissue obtained from patients undergoing surgical procedures on the breast. This Repository will serve as a necessary and needed resource for epidemiologists, and clinical and basic scientists who need a comprehensive and well documented storehouse of serum and breast tissue for research in breast biology and breast cancer. Specimens from the Repository will be allocated primarily to investigators in Kansas, Missouri, and the Southern Great Plains States after proper institutional review of requests. It is hoped that this Repository will enhance research in normal breast biology and breast cancer at the University of Kansas and regionally and assist in the search for better methods for early detection, diagnosis, and treatment of breast cancer.

The University of Kansas Medical Center asks for your participation in the Repository. Participation is voluntary and whether or not you choose to participate, the quality of your care by your physicians will not be affected in any way now or in the future. If you agree to participate, patient confidentiality will be strictly observed. Participation will entail the completion of a health history questionnaire, the signing of consent forms for the use of blood and tissue for research, and the donation of blood and a sample of the tissue removed during surgery. The questionnaire and consent forms are included in this packet. If you agree to participate, then bring this packet with completed questionnaire and consent forms (signed in the presence of a witness) with you on your surgery day. The packet may be left at the patient holding area of Same Day Surgery. Any questions you may have about the forms should be addressed to the Repository technician prior to the scheduled surgery date. A blood sample will be drawn, either during a scheduled clinic appointment prior to surgery, in the operating room, or during your post-operative appointment. Tissue samples, if available, will be provided to the Repository from the Surgical Pathology Laboratory where all tissues are sent for postsurgical examination.

Thank you for your cooperation,

Jonathan J. Di, Ph.D.

Director Division of Etiology and Prevention of Hormonal Cancers

Director Tissue and Serum Repository University of Kansas Cancer Institute

University of Kansas Medical Center

### TISSUE and SERUM REPOSITORY INFORMED CONSENT

### INTRODUCTION

I understand that as a person who will be undergoing biopsy or oncologic-related surgery I am being invited to participate in the University of Kansas Cancer Institute Tissue and Serum Repository. This repository will be located at the University of Kansas Medical Center.

### **PURPOSE**

The purpose of this repository is to store tissue, blood sera, plasma, and lymphocytes and make these materials available to cancer research investigators at the University of Kansas Medical Center and to other cancer research investigators in the region. The researchers will be studying what causes cancer, who will develop this disease, and how cancer can be detected at an early stage. The tissue and blood will be used for research using biological, biochemical, and molecular approaches.

### **PROCEDURE**

My participation in this repository will require two extra vials of blood being drawn in the Outpatient Laboratory or in the Cancer Center Outpatient Clinic or in the operating room. This is equivalent to approximately 4 teaspoons of blood. Extra tissue, if available, will be provided to the Repository by the Laboratory of Surgical Pathology. In addition, I will be asked to complete a Personal Health History Questionnaire. It will take about 15 minutes to complete the questionnaire.

### **RISKS**

Drawing blood may cause pain, bruising and very rarely infection.

### **BENEFITS**

This repository will probably not benefit me directly. This effort may help society learn more about cancer.

### **PAYMENT TO SUBJECTS**

I will not be paid for contributing to the Tissue and Serum Repository.

#### COSTS

There will be no cost to me for contributing to the Repository.

### INSTITUTIONAL DISCLAIMER STATEMENT

"You are authorized all necessary medical care for injury or disease which is the proximate result of your participation in this research. If I believe I have been injured as a result of participating in research, I should contact the Office of Legal Counsel, University of Kansas Medical Center, Kansas City, Kansas 66160-7101."

#### CONFIDENTIALITY

I understand the investigators will keep confidential all research related records and information from this study. However, I realize that sometimes the investigators will need to let others look at records of my participation. I agree to let representatives of the Department of the Army, U.S. Army Medical Research and Development Command and representatives of other research investigators who use my

tissue and/or serum in their research see my records. I understand that Repository investigators will not reveal my identity in any published material related to the Tissue and Serum Repository.

### **USE**

I understand that there is a possibility that the blood and tissue samples which I am providing under this study may also be used in other research studies and could potentially have some commercial applicability.

### **QUESTIONS**

I have read the information in this form. The investigators have answered my questions to my satisfaction. I know if I have any more questions after signing this form, I may contact the Director of the Tissue and Serum Repository, Dr. Jonathan J. Li at (913) 588-4742. If I have any questions about my rights as a research subject I may call (913) 588-1240 or write the Human Subjects Committee, University of Kansas Medical Center, 5012 Wescoe, 3901 Rainbow Blvd., Kansas City, Kansas, 66160-7700.

### **CONSENT**

The investigator(s) have given me information about what will be done to me by participating in the Repository and research studies. They also told me how it will be done, what I will have to do, and the purposes of the Repository and research. They have informed me about any inconvenience and discomfort or risks that I may experience due to my participation. They explained to me how my participation may affect me or my health. I agree to contribute blood and tissue to the Repository as a research subject. I am aware that I may refuse to answer any questions on the questionnaire or I may refuse any part of the research study. I understand that refusing to participate in the Repository will have no effect upon the medical care or treatment I receive in the future. I understand that the investigators will give me a copy of this form to keep for my records.

	Type/Print Subject's name
Date	Subject's Signature
WITNESS (to subject's signature of	of document)
Date	Witness Signature
	•
RESPONSIBLE INVESTIGATOR	R (Director of the Tissue and Serum Repository)

### BREAST SERUM REPOSITORY

I voluntarily and freely donate any and all serum samples to the U.S. Government and hereby relinquish all right, title, and interest to said items.

	Type/Print Subject's Name
Date	Subject's Signature
Date	Witness' Signature

### GENERAL INFORMATION

Today's Date:			
1. Please write in your birth date:(Mo	onth, Day,	Year)	
2. What is your height?			
3. What is your current weight?			
4. How would you describe yourself?			
White/Caucasian		1	
Black/African-American			(circle one number)
Latino/Hispanic/Mexican-American		3	(,
Asian/Oriental/Pacific Islander		4	
American Indian/Native Alaskan		5	
Other: Specify	_	6	
5. What is your religion?			
Catholic	1		
Protestant	2		
Mormon		(circle o	one number)
Seventh Day Adventist		`	•
Baptist	5		
Jewish	6		
None	7		
Other: Specify			
6. What is your current occupation? If you are no last occupation?			nat was your
7. What is your current marital status?			
Single	1		
Married	2	(circle one num	lber)
Divorced	3		
Widowed	4		
8. Where were you born?			-
City	State	· (	Country
9. Where is your current permanent residence?		~	<b>G</b>
	City	County	State
10. When did you start residing at your current pe	ermanent	residence?	
		(N	Ionth, Day, Year)

11. Where did you reside the longest up to the age of 18?			
Cit		State	Country
12. If foreign born, when did you immigrate to the United Sta	ites?		
12. If foreign born, when all you manigrate to the content of	Ye		
13. How much school did you complete?			
· · · · · · · · · · · · · · · · · · ·	1		
Some elementary		(-:1	
Elementary	2	(circle c	one number)
Some high school	3		
High school diploma/GED	. 4		
Vocational/Technical school	5		
Some college	6		
College degree	7		
•	8		
Some post-graduate	_		
Post-graduate degree	. 9		
14. To the best of your knowledge, what is your approximate	annual co	mbined hou	sehold
income, including investment income, retirement income,			
Under \$15,000	0,01.		
•	2	(-:1	
\$15,000-\$25,000	2	(circle o	one number)
\$25,000-\$35,000	3		
\$35,000-\$50,000	4		
\$50,000-\$100,000	5		
Over \$100,000	6		
	0		
15. What is the number of individuals supported by this incon	ıe?		
HEALTH AND MEDICAL HISTORY			
16. How old were you when you first started having your period	od?		
17. Have you ever experienced an irregular menstrual cycle?			
	e number	)	
No2	io mannoon	,	
No 2			
18. If you answered no to the above question, please skip to q			
If you answered yes to the above question, please describe	how your	menstrual (	cycle
was irregular			
How long was it irregular?			
Have you ever taken prescription drugs to correct irregula	rities in yo	our cycle?	
Yes 1 (circle one numb		-	
No 2			

months o	ne of the		0, ,	Months/Years	taken
		istruating?	,		
			(	circle one number)	
			,•	1.1	
	nswerea use?		ve question,	at what age did you e.	xperience
20. Have ye	ou had a	hysterectomy?	,		
			((	circle one number)	
If you a	nswered	yes to the abo	ve question,	at what age did you h	nave
a hystere	ctomy?_				
0.1 . 17	1		novad?		
•	•	our ovaries ren		circle one number)	
			()	sitcle one number)	
	sure				
			wa quartion	did you have one or	both ovaries removed?
		moved	ive question, 1	, aid you have one or i	boin ovaries removed:
	-		2	(circle one num	her)
		removed	3	(circle one nam	iber)
NOL	sure	•••••	3		
22. Are you	a DES a	laughter?			
-			((	circle one number)	
	•••••			ŕ	
) ? Have w	u ever u	sed birth contr	ral pills?		
-				ne number)	
			(011010 01		
			e auestion, p	lease skip to question	: #2 <b>4</b> .
					en you first began using
			1	•	, , o
			you use the	<i>pill?</i> (mo	nth/year)- <i>circle one</i>
					ou know the composition and
		de that inform			
		-		omposition	Dose

24. Have you ever be			
Yes	1 (c	ircle one number)	
No	2		
If you answered y	ves to the above question,	please answer the fo	ollowing questions. If any of
	o not apply to you, you ma		
a. How many	live births have you had?		
b. How many	miscarriages have you ha	d?At wh	eat age(s)?
c. How many	abortions have you had?_	At what a	ige(s)?
	er of weeks gestation at ti		
	oral contraceptives prescr		
	Yes 1		mber)
	No 2	•	,
If you	answered yes to the above	e auestion, how long	g did you take the oral
	ceptives?	1	,
	ere you when your first ch	ild was born?	
e. How old we	ere you when your last chi	ld was born?	
	east-feed any of your child		
•	1		
	2		
		stion, how many tote	al months did you breast-feed
	children?		, , ,
How old we	re you when you first bred	ist-fed a child?	
		·	
25. Have vou ever tal	ken drugs to induce ovulat	ion (for infertility)?	
<u>-</u>	1 (circle on		
No	2		
If you answered n	o to the above question, p	lease skip to questi	on # 26.
	es to the above question, I		
	ovulation?		
	s or years did you use the	m?	
	me of the drug(s) that you		
	Name of the drug(s)		
		<u>-</u>	
26. Have you ever use	ed hormone replacement n	nedications?	
Yes	1 (circle on	e number)	
No	2		
	o to the above question, p		
If you answered <b>y</b>	es to the above question, l	how old were you w	hen you first began using
hormone replacer	nent drugs?	_	
	s or years did you use the		(month/year)-circle one
	eplacement medication(s)		
Estrog	en (Premarin) & Progeste	rone (Provera)	1
Estrog	en (Premarin)		2 (circle all that apply)
Other	Specify		3

27. Have you ever to	ıken a prescripi 1			a year or more:
No		(onoio ono m		
If you answered i		auestion, pleas	e skip to auestio	on #28.
				of the drug(s) that you used
and for what purp				<b>3</b>
•	e of the drug			Purpose
				•
28. Have you ever he	ad a breast biop	osy?		
Yes				
No				
If you answered				on # 29.
If you answered		_	many?	
List the month a				
Month/Year	Month/Year	Month/Year	Month/Year	
		<del></del>		
20.4	1. 1 1	. 1 * 9		
29. Are you schedule				
Yes		(circle one nu	moer)	
No	2			
30. Have you ever ho	ad any other car	ncer-related su	rgeries?	
Yes		(circle one nu		
No		(011010 0110 110		
If you answered		auestion, pleas	se skip to auestic	on # 31.
				f surgery and the month/year
the surgery took p		<b>4</b> , <b>F</b>		3 3
	ery Type	Monti	h/Year	
28				
			<del></del>	
31. Have you ever be	een diagnosed w	vith benign bred	ast disease?	
Yes	1	(circle one nu	mber)	
No	2			
		,, , , , ,	, ,	
32. Has a <u>blood</u> rela	tive ever been d	liagnosed with	breast cancer?	
Yes	1			
No	2			
Not Sure			a alala da assassi	# 22
If you answered n	to the above (	question, pieasi	e skip to question	า # วว.

32. (continued) If you answered yes (circl	, what is the re e all that apply		u?			
Mother  Sister  Daughter  Maternal Grandmother  Paternal Grandmother		Maternal Aunt  Paternal Aunt  Other:Specify*  *Please note maternal/paternal	7			
Yes 1 No 2						
DIET AND LIFESTYLE						
34. Have you ever consumed alcohood Yes 1 No 2 If you answered no to the above If you answered yes to the above drinking regularly?	(circle one nu question, pleas question, how	amber) se skip to question #35.				
Do you still drink? Yes 1 No 2 Approximately how many of each 4 ounces wine, or 1.5 ounces of 1 BeerWineLiquor		verage (one beverage=12 ounce	es beer,			
If you are no longer drinking, at	what age did y	ou stop?				
35. Do you drink coffee? Yes 1 No 2 If you answered no to the above	(circle one nu					
If you answered yes to the above following types listed?  Regular (per day/pe Decaffeinated (per day/pe	r week)- <i>circle</i>	one	ink of the			

36. Do you drink co	la beverage	es?
Yes	1	(circle one number)
No	2	
If you answered	<b>no</b> to the a	above question, please skip to question #37.
If you answered	yes to the d	above question,how many 12 ounce servings do you drink of th
following types l	isted.	
Regular	(per da	y/per week)-circle one
Caffeine Fre	e(	per day/per week)-circle one
37. Do you drink tea	ı?	
Yes		
No	2	
If you answered	no to the a	bove question, please skip to question #38.
If you answered	yes to the d	above question, how many cups of tea do you drink of the
following types li	sted?	
		per week)-circle one
		er week)-circle one
		per week)-circle one
38. Are you a vegeta	rian?	
Yes		(circle one number)
No	2	
39. Do you currently	smoke?	
Yes		(circle one number)
No	2	
If you answered	<b>no</b> , did yoı	ı <u>ever</u> smoke?
Yes	1	(circle one number)
No	2	
If you answered	yes to eithe	er question above, at what age did you
start smoking?		
At what age did	you quit sn	10king?
How many packs		

Thank you for your cooperation in completing this form.

ITEM 2

## The University of Kansas Medica



### To: All Patients Scheduled for Gynecological Surgery

A Request for Participation in the Tissue and Serum Repository

The University of Kansas Medical Center has established a Tissue and Serum Repository. One main purpose of this Repository is to document, cryopreserve, and store serum and samples of endometrial and ovarian tissue obtained from patients undergoing gynecological surgery. This Repository will serve as a necessary and needed resource for epidemiologists, and clinical and basic scientists who need a comprehensive and well documented storehouse of serum and gynecological tissue for research in endometrial/ovarian biology and endometrial/ovarian cancer. Specimens from the Repository will be allocated primarily to investigators in Kansas, Missouri, and the Southern Great Plains States after proper institutional review of requests. It is hoped that this Repository will enhance research in normal endometrial/ovarian biology and endometrial/ovarian cancer at the University of Kansas and regionally and assist in the search for better methods for early detection, diagnosis, and treatment of endometrial and ovarian cancers.

The University of Kansas Medical Center asks for your participation in the Repository. Participation is voluntary and whether or not you choose to participate, the quality of your care by your physicians will not be affected in any way now or in the future. If you agree to participate, patient confidentiality will be strictly observed. Participation will entail the completion of a health history questionnaire, the signing of consent forms for the use of blood and tissue for research, and the donation of blood and a sample of the tissue removed during surgery. The questionnaire and consent forms are included in this packet. If you agree to participate, then bring this packet with completed questionnaire and consent forms (signed in the presence of a witness) with you on your surgery day. The packet may be left at the patient holding area of Same Day Surgery. Any questions you may have about the forms should be addressed to the Repository technician prior to the scheduled surgery date. A blood sample will be drawn, either during a scheduled clinic appointment prior to surgery, in the operating room, or during your post-operative appointment. Tissue samples, if available, will be provided to the Repository from the Surgical Pathology Laboratory where all tissues are sent for postsurgical examination.

Thank you for your cooperation,

Jonathan J. Li, Ph.D.

Director Division of Etiology and Prevention of Hormonal Cancers

Director Tissue and Serum Repository University of Kansas Cancer Institute

University of Kansas Medical Center

### ENDOMETRIAL AND OVARIAN TISSUE REPOSITORY

I voluntarily and freely donate any and all tissue samples to the U.S. Government and hereby relinquish all right, title, and interest to said items.

	Type/Print Subject's Name
Date	Subject's Signature
Date	Witness' Signature

### ENDOMETRIAL AND OVARIAN SERUM REPOSITORY

I voluntarily and freely donate any and all serum samples to the U.S. Government and hereby relinquish all right, title, and interest to said items.

	Type/Print Subject's Name
Date	Subject's Signature
Date	Witness' Signature

## The University of Kansas Medica



### To: All Patients Scheduled for Prostate Surgery

A Request for Participation in the Tissue and Serum Repository

The University of Kansas Medical Center has established a Tissue and Serum Repository. One main purpose of this Repository is to document, cryopreserve, and store serum and samples of prostate tissue obtained from patients undergoing surgical procedures on the prostate. This Repository will serve as a necessary and needed resource for epidemiologists, and clinical and basic scientists who need a comprehensive and well documented storehouse of serum and prostate tissue for research in prostate biology and prostate cancer. Specimens from the Repository will be allocated primarily to investigators in Kansas, Missouri, and the Southern Great Plains States after proper institutional review of requests. It is hoped that this Repository will enhance research in normal prostate biology and prostate cancer at the University of Kansas and regionally and assist in the search for better methods for early detection, diagnosis, and treatment of prostate cancer.

The University of Kansas Medical Center asks for your participation in the Repository. Participation is voluntary and whether or not you choose to participate, the quality of your care by your physicians will not be affected in any way now or in the future. If you agree to participate, patient confidentiality will be strictly observed. Participation will entail the completion of a health history questionnaire, the signing of consent forms for the use of blood and tissue for research, and the donation of blood and a sample of the tissue removed during surgery. The questionnaire and consent forms are included in this packet. If you agree to participate, then bring this packet with completed questionnaire and consent forms (signed in the presence of a witness) with you on your surgery date. The packet may be left at the Cancer Center front desk. Any questions you may have about the forms should be addressed to the Repository technician prior to the surgery date. A blood sample will be drawn, either during your scheduled clinic appointment prior to surgery or during your post-operative appointment. Tissue samples, if available, will be provided to the Repository from the Surgical Pathology Laboratory where all tissues are sent for postsurgical examination.

Thank you for your cooperation,

Jonathan L. Li, Ph.D.

Director Division of Etiology and Prevention of Hormonal Cancers

Director Tissue and Serum Repository

University of Kansas Cancer Institute

University of Kansas Medical Center

### TISSUE and SERUM REPOSITORY INFORMED CONSENT

### INTRODUCTION

I understand that as a person who will be undergoing biopsy or oncologic-related surgery I am being invited to participate in the University of Kansas Cancer Institute Tissue and Serum Repository. This repository will be located at the University of Kansas Medical Center.

### **PURPOSE**

The purpose of this repository is to store tissue, blood sera, plasma, and lymphocytes and make these materials available to cancer research investigators at the University of Kansas Medical Center and to other cancer research investigators in the region. The researchers will be studying what causes cancer, who will develop this disease, and how cancer can be detected at an early stage. The tissue and blood will be used for research using biological, biochemical, and molecular approaches.

### **PROCEDURE**

My participation in this repository will require two extra vials of blood being drawn in the Outpatient Laboratory or in the Cancer Center Outpatient Clinic or in the operating room. This is equivalent to approximately 4 teaspoons of blood. Extra tissue, if available, will be provided to the Repository by the Laboratory of Surgical Pathology. In addition, I will be asked to complete a Personal Health History Questionnaire. It will take about 15 minutes to complete the questionnaire.

### **RISKS**

Drawing blood may cause pain, bruising and very rarely infection.

### **BENEFITS**

This repository will probably not benefit me directly. This effort may help society learn more about cancer.

### **PAYMENT TO SUBJECTS**

I will not be paid for contributing to the Tissue and Serum Repository.

### **COSTS**

There will be no cost to me for contributing to the Repository.

### INSTITUTIONAL DISCLAIMER STATEMENT

"You are authorized all necessary medical care for injury or disease which is the proximate result of your participation in this research. If I believe I have been injured as a result of participating in research, I should contact the Office of Legal Counsel, University of Kansas Medical Center, Kansas City, Kansas 66160-7101."

### CONFIDENTIALITY

I understand the investigators will keep confidential all research related records and information from this study. However, I realize that sometimes the investigators will need to let others look at records of my participation. I agree to let representatives of the Department of the Army, U.S. Army Medical Research and Development Command and representatives of other research investigators who use my

tissue and/or serum in their research see my records. I understand that Repository investigatorÕs will not reveal my identity in any published material related to the Tissue and Serum Repository.

### **USE**

I understand that there is a possibility that the blood and tissue samples which I am providing under this study may also be used in other research studies and could potentially have some commercial applicability.

### **OUESTIONS**

I have read the information in this form. The investigators have answered my questions to my satisfaction. I know if I have any more questions after signing this form, I may contact the Director of the Tissue and Serum Repository, Dr. Jonathan J. Li at (913) 588-4742. If I have any questions about my rights as a research subject I may call (913) 588-1240 or write the Human Subjects Committee, University of Kansas Medical Center, 5012 Wescoe, 3901 Rainbow Blvd., Kansas City, Kansas, 66160-7700.

### **CONSENT**

The investigator(s) have given me information about what will be done to me by participating in the Repository and research studies. They also told me how it will be done, what I will have to do, and the purposes of the Repository and research. They have informed me about any inconvenience and discomfort or risks that I may experience due to my participation. They explained to me how my participation may affect me or my health. I agree to contribute blood and tissue to the Repository as a research subject. I am aware that I may refuse to answer any questions on the questionnaire or I may refuse any part of the research study. I understand that refusing to participate in the Repository will have no effect upon the medical care or treatment I receive in the future. I understand that the investigators will give me a copy of this form to keep for my records.

	Type/Print Subject's name
Date	Subject's Signature
WITNESS (to subject's signature of	of document)
Date	Witness Signature
RESPONSIBLE INVESTIGATOR	(Director of the Tissue and Serum Repository).
11/25/1998	tudlan n
Date	Responsible Investigator's Signature

### PROSTATE TISSUE REPOSITORY

I voluntarily and freely donate any and all tissue samples to the U.S. Government and hereby relinquish all right, title, and interest to said items.

	Type/Print Subject's Name
Date	Subject's Signature
Date	Witness' Signature

### PROSTATE SERUM REPOSITORY

I voluntarily and freely donate any and all serum samples to the U.S. Government and hereby relinquish all right, title, and interest to said items.

	Type/Print Subject's Name
Date	Subject's Signature
Date	Witness' Signature

# KANSAS CANCER INSTITUTE TISSUE AND SERUM REPOSITORY

### PROSTATE CANCER QUESTIONNAIRE

DO NOT WRITE YOUR NAME ANYWHERE ON THIS SURVEY

1. The following questions are about activities you might do during a typical day. <u>Does your health</u> now limit you in these activities? If so, how much? (Circle 1, 2, or 3 on each line) Yes Yes No Not Limited Limited Limited A Lot A Little At All a. Vigorous activities, such as running, 2 3 1 lifting heavy objects, participating in strenuous sports..... b. Moderate activities, such as moving a 2 3 1 table, pushing a vacuum cleaner, bowling, or playing golf..... 2 3 c. Lifting or carrying groceries..... 1 Climbing several flights of stairs..... 1 2 3 d. 2 3 Climbing one flight of stairs..... f. Bending, kneeling or stooping..... 1 2 3 Walking more than a mile..... 2 3 2 3 Walking several blocks..... h. 1 i. Walking one block..... 1 2 3 2 3 Bathing or dressing yourself..... j. 2. During the past 4wks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health? (please answer yes or no for each question by circling 1 or 2 on each line) <u>Yes</u> No 2 Cut down the amount of time you spent on work or other activities..... 1 2 Accomplished less than you would like..... 1 2 Were limited in the kind of work or other activities..... d. Had difficulty performing the work or other activities (for example, it 2 took extra effort).....

3. During the **past 4 wks**, have you had any of the following problems with your work or other regular daily activities <u>as a result of an **emotional problems**</u>, such as feeling depressed or anxious?

(Please answer yes or no for each question by circling 1 or 2 on each line)

		<u>res</u>	<u>No</u>
a.	Cut down the amount of time you spent on work or other activities	1	2
b.	Accomplished less than you would like	1	2
c.	Didn't do work or other activities as carefully as usual	1	2

4. These questions are about how you feel and how things have been with you during the past 4wks. For each question, please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 wks.........

(Circle one number on each line)

				A Good part of Time			None of the <u>Time</u>
a.	Did you feel full of pep?		1	2 3	4	5	6
b.	Have you been a very nervous person?		1	2 3	3 4	. 5	6
c.	Have you felt so down in the dumps that nothing could cheer you up?	<b></b>	1	2 3	4	5	6
d.	Have you felt calm and peaceful?		1	2	3 4	5	6
e.	Did you have a lot of energy?		1	2 3	3 4	5	6
f.	Have you felt downhearted and blue?	••••	1	2	3 4	1 5	6
g.	Did you feel worn out?		1	2 3	3 4	. 5	6
h.	Have you been a happy person?		1	2	3 4	4 5	6
i.	Did you feel tired?	• • • •	1	2	3 4	1 5	6

5.	During the past 4 wks, how much of the time has your phinterfered with your social activities (like visiting with fractional activities)	· · · · · · · · · · · · · · · · · · ·
	Most of the time2	(Circle one number)
	Some of the time3	
	A little of the time4	
	None of the time5	
6.	During the <b>past 4 wks</b> , to what extent has your physical is your normal social activities with family, friends, neighb  Not at all	ors, or groups?
	Slightly2	(Circle one number)
	Moderately3	
	Quite a bit4	
	Extremely5	
7.	How much bodily pain have you had during the <b>past 4 w</b> None1	ks?
	Very mild2	(Circle one number)
	Mild3	
	Moderate4	
	Severe5	
	Very Severe6	
8.	During the <b>past 4 wks</b> , how much did <b>pain</b> interfere with outside the home and housework)?  Not at all1	your normal work (including both work
	Slightly2	(Circle one number)
	Moderately3	
	Quite a bit4	
	Extremely5	

Page 4

9.	Please choose the answer that best describes how true or false each of the following statements is for
	ou.

(Circle one number on each line)

		Definitely <u>True</u>	Mostly <u>True</u>	Not Sure	Mostly <u>False</u>	Definitely <u>False</u>
a.	I seem to get sick a little easier than other people	1	2	3	4	5
b.	I am as healthy as anyone I know	1	2	3	4	5
c.	I expect my health to get worse	1	2	3	4	5
d.	My health is excellent	1	2	3	4	5

10.	In gener	al, would	you say	your	health	is:
-----	----------	-----------	---------	------	--------	-----

Excellent	1	
Very good	2	(circle one number)
Good	3	
Fair	4	
Poor	5	

11. Compared to one year ago, how would you rate your health in general now?

Much better now than one year ago1	
Somewhat better now than one year ago2	(circle one number)
About the same3	
Somewhat worse now than one year ago4	
Much worse now than one year ago5	

Ī	IR	IN	A	R	Y	Fί	IN	IC	TI:	O	N	i

URINARY FUNCTION: This section is about your urinary habits. Please consider only the last 4 wks.

12.	Over the past 4 wks, how often have given by Every day	1 2 3		circle one m	umber)	
13.	Which of the following best describes  No control whatsoever.  Frequent dribbling  Occasional dribbling  Total control			ring the last		
	14. How many pads or adult diapers per day did you usually use to control leakage during the last 4 wks?  3 or more pads per day					
15.	How big a problem, if any, has each (circle one number on each line)	of the follor	wing been for	you?		
		No <u>Problem</u>	Very Small Problem	Small <u>Problem</u>	Moderate <u>Problem</u>	Big <u>Problem</u>
	<ul><li>a. Dripping urine or wetting your pants</li><li>b. Urine leakage interfering</li></ul>		1	2	3	4
	with your sexual activity	0	1	Z	5	4
16.	Overall, how big a problem has your  No problem  Very small problem  Small problem  Moderate problem  Big problem	1 3 4		r you during		s?

## **BOWEL HABITS:**

The next section is about your bowel habits and abdominal pain. Please consider only the last 4 wks.

17.	How often have you had rectal urgency (felt like I had to pass stoo	l, but did not) during the last 4wks?
	More than once a day1	· · ·
	About once a day2	(circle one number)
	More than once a week3	
	About once a week4	
	Never5	
18.	How often have you had stools (bowel movements) that were loose during the last 4wks?	or liquid (no form, watery, mushy,)
	Never1	
	Rarely2	(circle one number)
	About half the time3	
	Usually4	
	Always5	
19	How much distress have your bowel movements caused you during	the last 4 wks?
	Severe distress1	•
	Moderate distress2	(circle one number)
	Little distress	(**************************************
	No distress4	
20	How often have you had crampy pain in your abdomen or pelvis d	uring the last 4 wks?
<i>: U</i> .	Several times a day	uring the tast 4 was.
	About once a day2	(circle one number)
	Several times a week	(energone number)
	About once a week4	
	About once this month	
	Rarely or never6	
21.	Overall, how big a problem have your bowel habits been for you a	uring the last 4 wks?
	Big problem1	
	Moderate problem2	(circle one number)
	Small problem3	
	Very small problem4	
	No problem5	

#### **SEXUAL HABITS:**

The next section is about your sexual function and sexual satisfaction. Many of the questions are very personal, but they will help us understand the important issues that you face every day. Remember, YOUR NAME DOES NOT APPEAR ANYWHERE ON THIS SURVEY. Please answer honestly about the last 4 wks only.

	(circle one number on each line)  Very <u>Poor Poor</u>	<u>Fair</u>	Good	Very <u>Good</u>
	a. Your level of sexual desire?	3 3 3	4 4 4	5 5 5
23.	How would you describe the ususal QUALITY of your erections?  None at all		(circle one	number)
24.	How would you describe the FREQUENCY of your erections?  I never had an erection when I wanted one		(circle one	e number)
25.	How often have you awakened in the morning or night with an erection?  Never		circle one	number)

26.	During the last 4 wks did you have vaginal or anal inte	ercourse?
	No1	(simple one number)
	Yes, Once2	(circle one number)
	Yes, More than once3	
27.	Overall, how would you rate your ability to function se.	xually during the last 4 wks?
	Very Poor1	
	Poor2	(circle one number)
	Fair3	
	Good4	
	Very Good5	
28.	Overall, how big a problem has your sexual function be         No problem       1         Very small problem       2         Small problem       3         Moderate problem       4         Big problem       5	een for you during the last 4 wks?  (circle one number)
29.	Overall, how satisfied are you with the treatment you re Extremely dissatisfied	eceived for your prostate cancer?  (circle one number)
	Satisfied4	
	Extremely satisfied5	

THANK YOU VERY MUCH!!!

## FINAL SECTION:

These last questions are about your household and your general medical history. These items are very important for our research. Please answer honestly, and DO NOT WRITE YOUR NAME ANYWHERE ON THIS SURVEY.

1.	How old were you on your last birthday?	
	years	
2.	How do you describe yourself?1White/Caucasian (not Latino/Hispanic)1Black/African-American (not Latino/Hispanic)2Latino/Hispanic/Mexican-American3Asian/Oriental/Pacific Islander4American Indian/Native Alaskan5	(circle one number)
	Other: Specify6	
<i>3</i> .	Which of the following best describes your current relationship?  Living with spouse or partner	(circle one number)
4.	What is your current marital status?  Never married	
5.	Are you now working at a paying job? Yes, full-fime	
6.	Do you smoke cigarettes?  No	

Page 2

Have you ever had any of the following treatments for prostate cancer?

Have you ever had any of the following		nts for prostate c	ancer?
(Please circle yes or no for every item	<u>N0</u>	Yes	
Radical prostatectomy (surgery to remove prostate)	1	2	Mth/yr of surgery
Radiation	1	2	Mth/yr completed
Orchiectomy (removal of testicles)	1	2	Mth/yr of surgery
Lupron/Zoladex shots	1	2	
Flutamide pills	1	2	
Other: Specify			
Have you ever had any of the following (please circle yes or no for every item)			NI.
		Yes	<u>No</u>
Diabetes		1 1	2 2
Heart attack, chest pain Stroke		1	2
Stroke Amputation		1	2
Circulation problems in legs	/feet	1	2
Asthma, emphysema, breathing problems 1			2
Stomach ulcer, irritable bowel 1			2
Kidney disease	-	1	2
Major depression		1	2
Seizures		1	2
Alcoholism or alcohol probl	ems	1	2
Drug problems		1	2
How much school did you complete?		1	
Grade school of less			
Some high school or technical school2  High school or technical school graduate3			
Some college4			
College graduate5			
Graduate or professional sch			
What is your approximate annual con			
Zero			
\$5,000 - \$10,0003			
\$10,000 - \$20,000			
\$20,000 - \$30,000			
\$30,000 - \$50,0006			
\$50,000 - \$75,000			THANK YOU VERY MUCH!!!!
More than \$75,000			
•			

# **Protocol for Breast Tissue Procu**



## Tissue and Serum Repository Kansas Cancer Institute University of Kansas Medical Center



#### I. BREAST CLINIC

#### A. BREAST SURGERY IS SCHEDULED

- 1. Clinic staff contacts TSR Coordinator
  - a) Office extension: 4766
  - b) Pager number: 917-6604
- 2. TSR Coordinator will consent patient in clinic
  - a) Information packet/Health History Questionnaire
  - b) Explanation of the Repository
  - c) Consent forms signed by participating patient
  - d) Participant receives copies of signed consents
- 3. TSR Coordinator will place patient information in the Repository Tracker
  - a) Name of patient
  - b) Hospital ID number
  - c) Date of surgery
  - d) Procedure type (biopsy,lumpectomy,mastectomy)
- 4. Blood samples are collected from participant in either the Cancer Center or the operating room
  - a) Serum Separator Vial---10 mL marble top
  - b) ACD Solution A Vial---10 mL yellow top
- 5. Blood samples are transported to the TSR laboratory for processing
  - a) TSR Coordinator will transport vials in an insulated container
  - b) Blood is processed, stored, and cataloged according to laboratory protocols
- 6. Health History Questionnaire
  - a) Patient may complete this questionnaire at home
  - b) Questionnaire and any consents may be returned in Same Day Surgery on the scheduled surgery day
    - i) Must be returned in the TSR envelope marked with the 'CONFIDENTIAL' label
    - ii) TSR Coordinator will pick-up the envelope in SDS from a predetermined location

#### II. SURGERY

4

#### A. BLOOD COLLECTION

- 1. TSR Coordinator will be dressed in appropriate OR attire
- 2. TSR Coordinator will bring two blood collection tubes to the operating room
  - a) Collect blood samples from only those patients who haven't donated blood, but have consented
  - b) Anesthesiologist will collect two vials of blood from patient
    - i) Serum Separator Vial---10 mL marble top
    - ii) ACD Solution A Vial---10 mL yellow top
- 2. Blood samples are transported to the TSR laboratory for processing.
  - a) TSR Coordinator will transport vials in an insulated container
  - b) Blood is processed, stored, and cataloged according to laboratory protocols

#### **B. TISSUE COLLECTION**

- 1. TSR Coordinator will meet with the OR staff at beginning of surgery
  - a) Remind staff to place the removed tissue in saline, not formalin
- 2. TSR Coordinator will meet with resident in Surgical Pathology who will be handling the case
  - a) Leave instructions to be contacted at time tissue is received by Surgical Pathology
  - b) TSR Coordinator should also exercise the habit of checking with Surgical Pathology from time to time, so as not to miss the opportunity to obtain tissue
- 3. Equipment for tissue procurement\*
  - a) 3 x 4 inch Zip-lock baggies
  - b) Baggies with fold down tops
  - c) Embedding molds for histology blocks
    - i) Pre-labeled with freezer space number (1 to 16)
  - d) Sharpie pen
  - e) Gloves
  - f) \*Equipment should be stocked in Surgical Pathology in a small container marked for TSR use only
- 4. Attempt to obtain both malignant tissue and adjacent benign tissue from patients with a pre-operative diagnosis of breast cancer
- 5. Cut small, 1 gram size pieces with a clean razor blade
- 6. Place the tissue samples into a baggie without a zip-lock in a single layer

- 7. Snap-Freeze in liquid nitrogen used by Surgical Pathology by lowering the tissue with a pair of long forceps
- 8. Place the frozen tissue in a nearby cryostat
- 9. Place the frozen tissue (in the baggie) into a pre-labeled zip-lock bag
  - a) Malignant or Benign
  - b) Right or Left breast
  - c) Number of samples
  - d) Name of patient
  - e) Surgical Pathology number
- 10. If a histology block will be made, place the baggie back into the cryostat
- 11. Prepare one histology block per breast, if enough tissue is available
  - a) Place a tissue sample in a pre-labeled mold with OCT medium
  - b) Cover with OCT and freeze over liquid nitrogen i)Use a lowering device supplied by Surgical Pathology
  - c) Place the histology block with the frozen tissue and store in the -70°C freezer until transport
- 12. Use the TSR igloo cooler to transport the tissue on ice from Surgical pathology to the TSR laboratory

# Protocol for Prostate Tissue Procurement



# Tissue and Serum Repository Kansas Cancer Institute University of Kansas Medical Center



#### I. UROLOGY CLINIC

#### A. PROSTATECTOMY IS SCHEDULED

- 1. Assisting nurse contacts TSR Coordinator
  - a) Office extension: 4766
  - b) Pager number: 917-6604
- 2. TSR Coordinator will consent patient in clinic
  - a) Information packet/Quality of Life Survey (QOL only for prostatectomy pts.)
  - b) Explanation of the Repository
  - c) Consent forms signed by participating patient
  - d) Participant receives copies of signed consents
- 3. TSR Coordinator will place patient information in the Repository Tracker
  - a) Name of patient
  - b) Hospital ID number
  - c) Date of surgery
  - d) Procedure type (RRP, RPP, Cysto)
- 4. TSR Coordinator and attending nurse begin filling out clinical forms (for prostatectomy patients only)
  - a) Registration
  - b) Staging
  - c) Prostate Ultrasound TRUS Report
- 5. TSR label will be placed on new participant's clinic file
  - a) Bright label (green) will signify a TSR participant
- 6. Resident notifies TSR Coordinator once clinical forms (1a.-1c.) are completed
  - a) Office extension: 4766, if no answer, leave voice mail
  - b) The resident may leave the forms in the urology clinic or the Urology department in predetermined locations
- 7. Quality of Life Survey
  - a) Patient will complete this survey and return to assisting nurse in

DEPHC/I:/JODI/PROSPROTOCOL.DOC

- b) Patient may also return QOL and any consents to Same Day Surgery on scheduled surgery day
  - i) Must be returned in the TSR envelope marked with the 'CONFIDENTIAL' label
  - ii) TSR Coordinator will pick-up the envelope in SDS or the urology clinic from a predetermined location

#### II. SURGERY

#### A. BLOOD COLLECTION

- 1. TSR Coordinator will be dressed in appropriate OR attire
- 2. TSR Coordinator will bring two blood collection tubes to the operating room
  - a) Anesthesiologist will collect two vials of blood from patient
    - i) Serum Separator Vial---10 mL marble top
    - ii) ACD Solution A Vial---10 mL yellow top
- 3. Blood samples are transported to the TSR laboratory for processing
  - a) TSR Coordinator will transport vials in an insulated container
  - b) Blood is processed, stored, cataloged according to laboratory protocols

#### **B. TISSUE COLLECTION**

- 1. OR staff will notify TSR Coordinator approximately 20 minutes prior to the removal of the prostate
- 2. TSR Coordinator will be dressed in appropriate OR attire
- 3. TSR Coordinator will bring tissue collection items to OR
  - a) Dry ice and liquid nitrogen
  - b) 2 Acu-Punch biopsy instruments
  - c) 4 Pre-labeled 2 mL cryovials
    - i) Barcode label
    - ii) Hand written barcode
    - iii) Hand written coolspot
    - iv) Numbered 1-4

- d) Extra cryovials for any additional punch biopsies
- e) Cryomarker to label any additional vials with subsequent number
- f) Prostatectomy Specimen Log form (PSL)
  - i) Tracks the locale of each punch biopsy from the prostate
  - ii) One punch biopsy per vial
- g) Radical Prostatectomy Pelvic Lymphadenectomy form (RPPL)
- h) Gloves
- 4. Surgeon removes prostate; single cut is made through the mid portion, exposing two mirror image halves from which separate specimens can be harvested
  - a) Prostate specimens obtained with an Acu-Punch biopsy instrument by the surgeon
  - b) TSR Coordinator wears gloves and opens first cryovial to receive specimen from surgeon
  - c) Cryovial containing the specimen is immediately placed in liquid nitrogen
  - d) TSR Coordinator notes the prostate specimen locale on the PSL
  - e) TSR Coordinator opens next cryovial and the same process is repeated
- 5. RPPL form is given to an attending resident to complete for TSR files
  - a) Form delivered in a bright green envelope
  - b) Resident contacts TSR Coordinator once form is completed
  - c) Resident may leave the forms in bright green envelope in the urology clinic or the Urology department in predetermined locations
- 6. TSR will transport blood samples and tissue back to the TSR laboratory for processing, storage, and cataloging



# **Tissue and Serum Repository**

Kansas Cancer Institute University of Kansas Medical Center



# Procurement of Prostate Tissue For the Sonic Hedgehog and Gli Study Northwestern University Medical School

#### I. PREPARE FIXATIVES & EtOH

#### A. PARAFORMALDEHYDE

- 1. Prepare fresh 4% PFA the morning of scheduled surgery
- 2. PFA recipe located in TSR Laboratory Protocols manual

#### B. FORMALIN

1. Obtain formalin in Surgical Pathology Laboratory

#### C. EtOH

1. Prepare a 70% EtOH solution for tissues to be placed after fixation

## II. LABEL SCINTILLATION VIALS FOR FIXATIVES & EtOH

- A. USE COLOR CODING LABELS (Avery 05473)
- B. PLACE LABELS ON THE LIDS OF (8) VIALS
  - 1. Red(2)
    - a) Label one-FORMALIN/TUMOR
    - b) Label other-FORMALIN/TUMOR/EtOH
  - 2. Blue(2)
    - a) Label one-FORMALIN/BENIGN
    - b) Label other-FORMALIN/BENIGN/EtOH
  - 3. Green(2)
    - a) Label one-PFA/TUMOR
    - b) Label other-PFA/TUMOR/EtOH
  - 4. Yellow(2)
    - a) Label one-PFA/BENIGN
    - b) Label other-PFA/BENIGN/EtOH
- C. PLACE FIXATIVES & EtOH IN LABELED VIALS

# III. LABEL (2) CRYOVIALS FOR SNAP-FROZEN TISSUES

- A. USE 2.0 mL GREEN-CAPPED CRYOVIALS
- B. LABEL(1) VIAL-TUMOR
- C. LABEL (1) VIAL-BENIGN
- D. LABEL BOTH VIALS WITH BARCODE

#### IV. PROSTATECTOMY SURGERY

#### A. TISSUE COLLECTION

- 1. Surgeon will biopsy a region of the prostate, which upon gross diagnosis is malignant
- 2. Surgeon will take a small portion of the biopsy and cut into thirds, 3mm x 3mm samples
  - a) One sample should be placed in pre-labeled 2 mL cryovial marked TUMOR (green-capped)
    - i. Snap-freeze in liquid nitrogen
    - ii. Snap-frozen samples will be designated with patient barcode, an 'S' for snap-frozen, followed by a 'T' for tumor (123-S-T is an example)
  - b) One sample should be placed in the *red* pre-labeled vial marked FORMALIN/TUMOR
  - c) One sample should be placed in the *green* pre-labeled vial marked PFA/TUMOR
  - d) Remaining portion of tissue is frozen for Dr. Thrasher's study. (See original protocol)
- 3. Surgeon will biopsy a region of the prostate, which upon gross diagnosis is benign
- 4. Surgeon will take a small portion of the biopsy and cut into thirds, 3mm x 3mm samples
  - a) One sample should be placed in pre-labeled 2 mL cryovial marked BENIGN (green-capped)
    - i. Snap-freeze in liquid nitrogen
    - ii. Snap-frozen samples will be designated with patient barcode, an 'S' for snap-frozen, followed by a 'B' for benign (123-S-B is an example)
  - b) One sample should be placed in the *blue* pre-labeled vial marked FORMALIN/BENIGN
  - c) One sample should be placed the *yellow* pre-labeled vial marked PFA/BENIGN
  - d) Remaining portion of tissue is frozen for Dr. Thrasher's study. (See original protocol)

- 5. Fix the tissues for 45 minutes, then place in corresponding EtOH vials---store in refrigerator (4°C) until processed/embedded
- 6. Place the snap-frozen tissues in the freezer for temporary storage

## V. TISSUE PROCESSING AND EMBEDDING

#### A. PREPARATION FOR SURGICAL PATHOLOGY

- 1. Label (4) 1.5 mL microtest tubes
  - a) Patient barcode number
  - b) PFA or Formalin
  - c) Tumor or Benign
- 2. Transfer tissue to corresponding microtest tube
  - a) Use clean forceps
- 3. Tissues should be kept at 4°C until transported to Pathology
- 4. Tissues will be transported to Pathology on Fridays
- 5. Surgical Pathology staff will label cassettes
  - a) Patient barcode number
  - b) 'P' for Paraformaldehyde-fixed; or 'F' for Formalin-fixed
  - c) 'T' for Tumor tissue; or 'B' for Benign tissue
  - d) Example: '123-P-T' for barcode 123, PFA-fixed, Tumor
  - e) Tissue will be processed and embedded
- 6. Surgical Pathology staff will contact TSR Coordinator for pick-up
- 7. Embedded tissues will be transported to the TSR laboratory for storage at 4°C

#### VI. SHIPPING TISSUE

#### A. CONTACT AMERICAN ONE COURIER

- 1. Tissue will be shipped out after every tenth patient
- 2. Call the day before scheduled pick-up
  - a) Do not ship out over a weekend
- 3. Phone number: 1-800-445-9995
- 4. Always ship snap-frozen tissue with a freeze-thaw indicator

## B. CONTACT CHICAGO

1. Call Chicago at time of pick-up

2. Phone number: 1-312-908-8606

## C. CHICAGO RECEIVES TISSUE

1. TSR is contacted immediately; report given on condition of tissue

Grant #DAMD17-94-J-4294 - Final Report Pl: *Jonathan J. Li*, Ph.D. **ITEM 6** 



## Protocol for Serum Separation Tissue and Serum Repository

Kansas Cancer Institute University of Kansas Medical Center



Collect blood sample in a 10 mL Serum Separation tube. Keep the sample at room temperature for 1-2 hours, then follow this procedure:

- 1. Centrifuge at 1500 rpm for 15 minutes @ 4°C
- 2. Aliquot 1.5 mL serum into chilled cryovials which have been labeled with the assigned barcode and coolspot location
- 3. Freeze at -80°C
- 4. Note the coolspot locations, and aliquots in the database and patient file



# Protocol for Lymphocyte Separation Tissue and Serum Repository

# Kansas Cancer Institute University of Kansas Medical Center



## Collect blood sample in a 10 mL ACD tube and follow this procedure:

- In 4 separate 15 mL centrifuge tubes, pipet 3 mL LSM.
- In a 50 mL Falcon tube dilute blood in equal volume of Hank's (8 mL).
- ► Layer ~ 4 mL of diluted blood into each of the 15 mL tubes w/ LSM.
- ► Centrifuge @ 1380 rpm for 23 minutes.
- Aspirate lymphocyte layer from each tube (plus ½ of the LSM layer below it).
- ► Pipet the lymphocytes to one 15 mL centrifuge tube.
- Add equal volume of Hank's (~ 5 mL). Cap tightly and invert gently 2 times.
- ► Centrifuge @ 1000 rpm for 10 minutes. (This is the 1st rinsing step.)
- ▶ Decant supernantant, leaving the pellet. Add 5 mL Hank's and resuspend pellet.
- ► Centrifuge @ 1000 rpm for 10 minutes. (This is the 2nd rinsing step.)
- ► Using a 5 mL pipet, draw off the supernatant being careful not to disturb the pellet.
- Resuspend the pellet in 0.5 mL Hank's.
- Pipet the cell solution into a pre-labeled cryovial, noting the amount minus 20 microliters.

  Before freezing cells, follow the instructions below to determine cell count.
- ▶ Note the coolspot location, and aliquots in the database and patient file

## **Protocol for Lymphocyte Separation**

- Continuation -

## **Determing Cell Count**

In a 1 mL eppendorf tube, stain 20 microliters of cell solution with 180 microliters of crystal violet stain. Be sure to vortex gently (setting 4) for 20 seconds. Load the hemocytometer and count the number of cells in the middle square in *both* grids. Determine number of cells by averaging those 2 counts. Here's the formula:

Total # cells per mm3 =  $\frac{\text{number of cells}}{\text{(1)* mm2}}$  x 10 (depth) X 10 (dilution factor)

\*Remember, for example, if 4 outer squares are counted in each grid, be sure to divide that count by 4 (mm2) in the formula.

# Committee on Human Tissue Specimen Usa Tissue and Serum Repository



Kansas Cancer Institute
University of Kansas Medical Center



William Jewell, M.D. Surgeon, Professor

Director, Kansas Cancer Institute

Jonathan J. Li, Ph.D. Director, BTSR Core Facility, Professor

Sara Antonia Li, Ph.D. Associate Director

Hormonal Carcinogenesis Laboratory

Kansas Cancer Institute

Patricia Thomas, M.D. Pathologist, Associate Professor

Carol Fabian, M.D. Medical Oncologist, Professor

Ossama Tawfik, M.D. Pathologist, Assistant Professor